ADVAXIS Forum: Community User: Salatgirl

Boom

On October 6, 2020, Advaxis, Inc. (the “Company”) received a notice (the “Notice”) from Aratana Therapeutics, Inc. (“Aratana”), dated September 17, 2020, indicating that Aratana is terminating the Exclusive License Agreement, dated March 19, 2014, by and between Aratana and the Company (the “Agreement”) and that such termination of the Agreement will be effective on December 21, 2020. Other than in respect of the Agreement, there is no material relationship between the Company and Aratana. Under the Agreement, the Company granted Aratana an exclusive, worldwide, royalty-bearing license, with the right to sublicense, certain of the Company’s proprietary technology to enable Aratana to develop and commercialize animal health products targeted for treatment of osteosarcoma and other cancer indications in animals. Aratana paid an upfront payment to the Company in the amount of $1 million upon signing of the Aratana Agreement. The Agreement also required Aratana to pay the Company (a) up to $36.5 million based on the achievement of milestones relating to the advancement of products through the approval process with the United States Department of Agriculture in the United States and the relevant regulatory authorities in the European Union, and up to an additional $15 million in cumulative sales milestones based on achievement of gross sales revenue targets for sales of any and all products for use in non-human animal health applications, or the Aratana Field (regardless of therapeutic area), and (b) tiered royalties starting at 5% and going up to 10%, paid based on net sales of any and all products (regardless of therapeutic area) in the Aratana Field in the United States. The Agreement required royalties for sales of products outside of the United States to be paid at a rate equal to half of the royalty rate payable by Aratana on net sales of products in the United States (starting at 2.5% and going up to 5%). The Agreement also required Aratana to pay the Company 50% of all sublicense royalties received by Aratana and its affiliates. In fiscal year 2019, the Company received approximately $8,000 in royalty revenue from Aratana.

↗️

Dann wäre der Effekt aber sehr mau gewesen 😄

Dito. Wie gesagt, die Poison Pill kann auch nur geschickter Trommelwirbel sein.

Kommen wird in jedem Fall was. Bin mal gespannt, ob es eine große Sache wird oder doch nur neue Ergebnisse der Studien

Poison Pill kann auch eine Fraud-PR sein, aber ein guter Swing ist bestimmt drin.

Ich hab mal EK gesenkt. Bald kommt was.

Danke, ja, soviel hab ich jetzt auch schon gelesen. Andere meinen, sie wollen eine feindliche Übernahme verhindern, weil sie schon einen Käufer haben.... Bin am Überlegen, ob ich mir eine Zockerposition reinnehmen soll....

Einige meinen, das wäre Anzeichen eines BO und der CEO will seinen arsch retten

Bitte*

Kann mich wer aufklären was das bedeutet? 🤔

PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for such dividend distribution is October 12, 2020. The rights plan expires, without any further action being required to be taken by the Company’s Board of Directors, on September 28, 2021.

Was war den da letzte Woche los ? Spike des Jahres?

Was eine verarsche hier! Hätt besser gestern den Mist verkauft....

Es ist sogar schlechter als gestern. Wahnsinn. Viele sind am vermeintlichen Boden rein und ratzfatz mit 40-50%. Die Bagholder haben nen ganz anderen EK